CytoSorbents Corporation (CTSO)

[Good Sport]

Third QTR 2021 Financial Results just posted:

Total revenue, including product sales and grant income, for Q3 2021 was $9.8 million, compared to $10.5 million in Q3 2020, a decrease of 7%.

Q3 2021 CytoSorb product sales were $8.9 million, down 13% compared to $10.2 million in Q3 2020.
Q3 2021 product sales in Germany were $3.7 million, a decrease of $1.1 million or 24% from product sales of $4.8 million in Germany in Q3 2020.
Core non-COVID-19 product sales for Q3 2021 were approximately $7.8 million, up 3% from approximately $7.5 million in Q3 2020.
Estimated Q3 2021 COVID-19 related sales were $1.1 million, compared to an estimated $2.7 million in Q3 2020.
Q3 2021 product gross margins were 82%, as compared to 74% in Q3 2020.
The Company maintains a healthy cash balance of $61.0 million at September 30, 2021 with no debt.

10q
https://ih.advfn.com/stock-market/NASDAQ/cytosorbents-CTSO/stock-news/86468763/quarterly-report-10-q

https://ih.advfn.com/stock-market/NASDAQ/cytosorbents-CTSO/stock-news/86468599/cytosorbents-reports-full-third-quarter-2021-finan

Link to today's 4:30pm est call:
https://viavid.webcasts.com/starthere.jsp?ei=1505348&tp_key=fc4e9855a2